Filing Flows › ARS Pharmaceuticals (SPRY) › Product revenue
ARS Pharmaceuticals (SPRY) Product revenue by quarter
ARS Pharmaceuticals' Product revenue was $33.4M in Q3 2026 (third quarter 2026), +27% from Q2 2026. Over the last 7 quarters it ranged from $7.8M (Q1 2025) to $33.4M (Q3 2026).
| Quarter | Product revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $33.4M | +27% | +7% |
| Q2 2026 | $26.2M | +50% | +105% |
| Q1 2026 | $17.5M | -14% | +125% |
| Q4 2025 | $20.3M | -35% | — |
| Q3 2025 | $31.3M | +145% | — |
| Q2 2025 | $12.8M | +65% | — |
| Q1 2025 | $7.8M | — | — |
Q3 2026 at a glance
ARS Pharmaceuticals, Q3 2026: revenue $37.7M (+16% year over year), operating margin -90.6%, net loss $35.6M, operating cash flow −$33.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is ARS Pharmaceuticals' Product revenue?
ARS Pharmaceuticals' Product revenue was $33.4M in Q3 2026 (third quarter 2026), +27% from Q2 2026.
How has ARS Pharmaceuticals' Product revenue changed?
Over the last 7 quarters it ranged from $7.8M (Q1 2025) to $33.4M (Q3 2026).